Myriad Genetics, Inc. (MYGN) fundamentals score
Myriad Genetics is a leading molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercialize molecular tests that help patients and providers uncover genetic insights.
In Vitro & In Vivo Diagnostic Substances · Healthcare · Listed on NASDAQ
Overall: 4.6 out of 10, Weak long-term fundamentals
- Growth: 3.0/10
- Profitability: 4.5/10
- Financial health: 3.2/10
- Earnings quality: 8.7/10
- Valuation: 5.3/10
Scores are calculated from Myriad Genetics, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10